Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Yunnan Baiyao Group To Revisit Fundraising

This article was originally published in PharmAsia News

Executive Summary

Yunnan Baiyao Group, a leading TCM company in China, has unconfirmed plans to try again to get private financing, according to industry insiders. Sources disclose that the firm has been experiencing business slowdown since 2007 due to production capacity shortfalls while its relocation project requires a large investment. The capital raised will be used to construct its new production park and fund-fixed assets. The manufacturing base, with a phase one investment of 1.08 billion yuan ($157 million), is designed to produce 14 formulations and has capacity to expand its current output five-fold to reach 10 billion yuan. It will introduce up-to-date pharmaceutical equipment from Germany to upgrade the production system's automation control level and efficiency. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts